August 17th, 2010
admin
News From The Journal Of Clinical Investigation: Aug. 16, 2010
PULMONARY: Can vitamin D reduce a complication of cystic fibrosis? The lungs of most individuals with cystic fibrosis are colonized by the mold Aspergillus fumigatus. In some this causes a condition known as allergic bronchopulmonary aspergillosis (ABPA), which is characterized by wheezing, lung infiltration by immune cells, and lung scarring, while others remain disease free…
Read more on Medical News Today
August 7th, 2010
admin
Agendia inaugurates new clinical genomics laboratory
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia’s offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia’s strong commercial expansion in the U.S. market, as well as the use of multiple …
Read more on News-Medical-Net
August 2nd, 2010
admin Adoption of healthy nutrition practices urged at 1st GCC Symposium on Clinical Nutrition
The call to adopt healthy nutrition practices was made by health and medical practitioners attending the 1 st GCC Symposium on Clinical Nutrition held recently at the Arrayan Hospital in Riyadh, Kingdom of Saudi Arabia (KSA). The event, which aimed at increasing awareness on the importance of following a healthy lifestyle and practicing proper nutritional habits, was organized by the Dr …
Read more on Zawya
July 29th, 2010
admin Positive results from phase I clinical trial of MultiStem in patients with AMI announced
Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.
Read more on News-Medical-Net
July 19th, 2010
admin Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC
Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).
Read more on News-Medical-Net
July 7th, 2010
admin Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed
Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
Read more on News-Medical-Net
Powered by Yahoo! Answers